Biopharmaceutical company OncoSec Medical (OTC:ONCS) said Thursday that its president and CEO, Punit Dhillon, will speak at the VC in the OC investor conference in California, on May 15th.
The conference will take place at the Hyatt Regency Huntington Beach,
in Huntington Beach, California. OncoSec Medical will speak at 4:25 pm
VC in the OC is the first of two signature events held each year by
OCTANe, a not-for-profit organization composed of technology executive
leaders, entrepreneurs, investors, and other capitalists and advisors in
the Orange County area.
This year's event will feature 14 investment presentations that are
seeking seed, series A, or later stage venture capital investment.
OnoSec Medical is an emerging drug-medical device company focused on
the design, development, and commercialization of medical approaches for
the treatment of solid cancers.
In April, OncoSec unveiled positive interim data from a phase IV
trial testing its OMS (OncoSec Medical System) ElectroChemotherapy
treatment in Europe.
The cancer therapy company uses its OMS electroporation delivery
system that applies short electric pulses to cells, causing the opening
of pores in the cell membrane, and allowing for the efficient and safe
delivery of immunotherapy or chemotherapy agents to treat a range of
solid tumour cancers.
The OMS electroporation system has proven to enhance cellular uptake,
effectively treating cancerous cells while sparing surrounding healthy
tissue cutting through the toxic side effects of current available
treatment options like chemotherapy, radiation and surgery.
The company announced last month interim analysis of data from 81
subjects in a phase IV study of patients with primary (new) and locally
recurrent squamous cell carcinoma of the head and neck.
The patients were treated with OMS ElectroChemotherapy, with the
study showing the therapy's ability to provide local tumour control and
quality of life outcomes that "compared favourably" to standard outcomes
associated with surgery, the company said.
In the interim analysis, local tumor control was achieved in 46 of
49, or 94 percent, of primary tumors and 12 of 21, or 57 percent, of